Mannkind (MNKD) Research & Development (2010 - 2026)
Mannkind (MNKD) posted quarterly Research & Development of $17.2 million for Q1 2026, up 56.33% year-over-year from $11.0 million in Q1 2025, and down 37.54% quarter-over-quarter from $27.6 million in Q4 2025.
Mannkind (MNKD) Research & Development (2010 - 2026) Analysis & Trends
Mannkind (MNKD) has reported Research & Development for 17 consecutive years, with $17.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 56.33% year-over-year to $17.2 million; the TTM figure through Mar 2026 stood at $72.6 million (up 54.7% YoY), while the FY2025 annual figure was $66.3 million, up 44.57% from the prior year.
- Research & Development declined to $17.2 million in Q1 2026 per MNKD's latest filing, from $27.6 million in the prior quarter.
- Across five years, Research & Development topped out at $27.6 million in Q4 2025 and bottomed at $3.5 million in Q1 2022.
- Historically, Research & Development has averaged $10.6 million across 5 years, with a median of $10.0 million in 2024.
- On a YoY basis, Research & Development climbed as much as 147.69% in 2025 and fell as far as 8.8% in 2025.
- Mannkind's Research & Development stood at $7.2 million in 2022, then increased by 29.07% to $9.2 million in 2023, then rose by 20.59% to $11.1 million in 2024, then soared by 147.69% to $27.6 million in 2025, then slumped by 37.54% to $17.2 million in 2026.
- Business Quant data shows MNKD's Research & Development at $17.2 million in Q1 2026, $27.6 million in Q4 2025, and $14.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Mannkind | 1.19 Bn | 1.08 Bn | 94.97 Mn | 18.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.00 Mn |
| Mar 31, 2026 | 17.23 Mn |
| Dec 31, 2025 | 27.59 Mn |
| Sep 30, 2025 | 14.06 Mn |
| Jun 30, 2025 | 13.68 Mn |
| Mar 31, 2025 | 11.02 Mn |
| Dec 31, 2024 | 11.14 Mn |
| Sep 30, 2024 | 12.93 Mn |
| Jun 30, 2024 | 11.82 Mn |
| Mar 31, 2024 | 10.01 Mn |
| Dec 31, 2023 | 9.24 Mn |
| Sep 30, 2023 | 9.99 Mn |
| Jun 30, 2023 | 6.45 Mn |
| Mar 31, 2023 | 5.61 Mn |
| Dec 31, 2022 | 7.16 Mn |
| Sep 30, 2022 | 4.14 Mn |
| Jun 30, 2022 | 4.89 Mn |
| Mar 31, 2022 | 3.54 Mn |
| Dec 31, 2021 | 3.89 Mn |
| Sep 30, 2021 | 3.66 Mn |